Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Habib Barakat

Pulmonary Disease Suffolk, VA Medical Doctor

NPI 1982660767 CMS profile 90347

2000 Meade Parkway, Suffolk, VA 23434

Open in the dashboard

General payments

$8,692

403 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Habib Barakat of Suffolk, VA is reported in the CMS Open Payments database as having received $8,692 across 403 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,456 58
2024 General $1,592 64
2023 General $1,682 74
2022 General $1,218 56
2021 General $797 42
2020 General $811 43
2019 General $1,137 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Habib Barakat
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Habib Barakat were reported at $1,456. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Habib Barakat Pulmonary Disease median Middle half National median
2019 $1,137 $377 $109–$1,340 $163
2020 $811 $230 $56–$907 $114
2021 $797 $269 $68–$1,072 $132
2022 $1,218 $390 $100–$1,457 $149
2023 $1,682 $419 $114–$1,659 $160
2024 $1,592 $476 $123–$1,818 $164
2025 $1,456 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,241 79 payments
  2. AstraZeneca Pharmaceuticals LP $1,173 48 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $720 42 payments
  4. Actelion Pharmaceuticals US, Inc. $562 22 payments
  5. Insmed, Inc. $454 17 payments
  6. Regeneron Healthcare Solutions, Inc. $426 20 payments
  7. Amgen Inc. $369 11 payments
  8. Merck Sharp & Dohme Corporation $362 15 payments
  9. Mallinckrodt Hospital Products Inc. $337 16 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $328 16 payments
  11. Other $2,720 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,373 396 payments
  2. Education $319 7 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $533 21 payments
  2. BREZTRI $524 19 payments
  3. TEZSPIRE Respiratory $523 7 payments
  4. TRELEGY ELLIPTA $510 34 payments
  5. NUCALA $490 31 payments
  6. Arikayce $454 17 payments
  7. SPIRIVA RESPIMAT $445 33 payments
  8. OPSUMIT $425 17 payments
  9. TEZSPIRE Inflammation $350 10 payments
  10. ACTHAR $337 16 payments
  11. Other $5,764 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,101

Median for Pulmonary Disease: 936

Drug cost

$884,565

Median for Pulmonary Disease: $487,987

Branded share of claims

66.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 29 $380,835
Arikayce Amikacin Liposomal/Neb.Accessr Brand 11 $169,618
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 158 $157,089
Breo Ellipta Fluticasone/Vilanterol Brand 54 $30,898
Eliquis Apixaban Brand 35 $29,668
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 42 $27,869
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 35 $27,869
Spiriva Respimat Tiotropium Bromide Brand 37 $23,920
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 20 $20,050
Albuterol Sulfate Hfa Albuterol Sulfate Brand 193 $3,724

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$165,214

Of which drugs: $2,465

Medicare patients

539

Average age 75

Services billed

2,032

289 women, 250 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 56%
Arthritis 55%
Heart failure 50%
Diabetes 46%
Ischemic heart disease 46%
Chronic kidney disease 44%
Atrial fibrillation 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 12 12 $972

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • Amgen Inc. $141
  • AstraZeneca Pharmaceuticals LP $119
$260 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $96
  • GENZYME CORPORATION $38
$134 — —
Leqembi
  • Eisai Inc. $125
$125 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $115
$115 29 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

403 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record